Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinomahttps://www.nct-dresden.de/en/trials/900-000002553https://www.nct-dresden.de/@@site-logo/logo-nct.svg
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Urogenital tumors
Renal cell carcinoma
Second line + Treatment (Metastatic Disease)
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifanversus placebo when each is given in combination with cabozantinib in adult patients withconfirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experiencedprogression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifanversus placebo when each is given in combination with cabozantinib in adult patients withconfirmed advanced or metastatic clear cell Renal Cell Carcinoma who have experiencedprogression on or after prior anti-PD-1 or anti-PD-L1 immunotherapy.
